Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Has Average Price Target of $31.29 According to Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $31.29.

Several brokerages recently commented on DYN. Robert W. Baird lowered their price target on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Wednesday, September 9th. Morgan Stanley reduced their target price on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Cantor Fitzgerald restated a “buy” rating on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Finally, Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st.

Dyne Therapeutics Price Performance

DYN opened at $18.62 on Thursday. The stock has a fifty day moving average price of $17.57 and a 200 day moving average price of $19.34. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics has a 1 year low of $14.00 and a 1 year high of $27.31. The stock has a market cap of $3.48 billion, a price-to-earnings ratio of -5.13 and a beta of 1.22.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period in the prior year, the business earned ($0.76) earnings per share. Analysts forecast that Dyne Therapeutics will post -3.69 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Brian Posner bought 2,500 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were bought at an average cost of $16.00 per share, for a total transaction of $40,000.00. Following the completion of the acquisition, the director directly owned 27,000 shares in the company, valued at approximately $432,000. This represents a 10.20% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at $6,749,732.16. This represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 2,598,706 shares of company stock valued at $65,432,671. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Dyne Therapeutics during the second quarter valued at approximately $275,500,000. Jupiter Topco LLC acquired a new stake in shares of Dyne Therapeutics in the second quarter worth $266,634,000. Bank of America Corp DE bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth $49,604,000. Palo Alto Investors LP bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth $36,591,441. Finally, Perceptive Advisors LLC boosted its holdings in shares of Dyne Therapeutics by 34.2% during the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock worth $84,646,000 after buying an additional 1,189,895 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy.